This was a notable shift from earlier positions:
The government had even explored last-ditch options in May 2026, including increasing the state's 12% stake in Commerzbank to block the deal — a plan that faced significant financial constraints .
After its tender offer closed on July 3, 2026, UniCredit secured an additional 17.6% of Commerzbank's shares, bringing its total to 47.6% of outstanding capital . When excluding Commerzbank's treasury shares — which carry no voting rights — UniCredit will hold 49.65% of the voting rights, well above the roughly 40% threshold that generally entails a position of control under German corporate rules
.
However, less than 2% of unaffiliated independent investors tendered their shares. The bulk of the additional stake came from the bidder's own financial instruments and existing stakes, fueling doubts about the true level of market support from outside UniCredit's circle . Commerzbank's stock slid 3.74% on the day the results were announced, falling to €36.77 from €38.20
.
Despite Merz's July reversal, the German government and Commerzbank's leadership had spent months fighting the deal:
The European Central Bank's authorization for UniCredit's full control is still pending, with expectations it could be granted no later than the third quarter of 2026. The exchange offer was structured at 0.485 UniCredit shares per Commerzbank share.
The main remaining hurdles are ECB approval, the ongoing market manipulation investigation by Frankfurt prosecutors, and the challenge of integrating a target that resisted the deal at every stage. The combination would create what multiple sources describe as "Europe's biggest bank merger in nearly two decades" and a deal valued at approximately €35 billion .
UniCredit has achieved de facto voting control of Commerzbank despite sustained opposition from the German government, Commerzbank's board, and workers. Merz's July 15 statement is a decisive political shift, effectively clearing the path for regulatory review by the ECB. The main remaining hurdles are ECB authorization (expected Q3 2026), the ongoing market manipulation investigation, and the challenge of integrating a target that resisted the deal at every stage.